News Sentiment

BIOA sentiment intelligence

BioAge Labs, Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 49 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 24.34 Week of 10 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

89/100 classification confidence.

Company focus 49

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

-3.0% over one week, +34.9% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

HitGen Partner BioAge Labs Doses First Participant In Phase 2 Trial Of BGE-102

Market Reaction

Balanced read

65/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 89/100 classification
One-week reaction -3.0% Price reacting lower
Trend fit Trend active 34.9% over four weeks
Fair value 114.7% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 12
Neutral 27
Negative 10

Relevance

Why the article matched

Direct first
Direct company coverage 49
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
TradingView 11
Stock Titan 6
Investing.com 4
Market source 4
Sahm 3
Investing.com Canada 3
simplywall.st 3
GlobeNewswire 3

Event Lens

What the news is about

Classified themes
Market update 40
Earnings 5
Analyst action 3
Macro sensitivity 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 49
Investing.com Direct company coverage

HitGen partner BioAge begins phase 2 trial of BGE-102

HitGen Inc. announced that its partner BioAge Labs has started a Phase 2 clinical trial for BGE-102, an oral small molecule NLRP3 inhibitor aimed at reducing cardiovascular risk. The trial, named QUELL-CV, will evaluate optimal dosing for future Phase 3 development and is expecte

Tone
Positive 91/100
Event
Market update
Published
14 Jul 2026 13:46
Source
Investing.com
PR Newswire Direct company coverage

HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction

HitGen's partner, BioAge Labs, has dosed the first participant in its Phase 2 QUELL-CV trial for BGE-102, a novel oral NLRP3 inhibitor developed using HitGen's DNA-Encoded Library (DEL) technology. This trial aims to determine optimal dosing for cardiovascular risk reduction, wit

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 13:30
Source
PR Newswire
Sahm Direct company coverage

How Broad Russell Growth Index Inclusion Could Shape BioAge Labs (BIOA) Investor Exposure

BioAge Labs (BIOA) was recently added to several Russell Growth Benchmark Indexes, increasing its visibility among institutional investors but not fundamentally changing its core investment risks or near-term catalysts. The investment case hinges on the success of its lead asset

Tone
Neutral 50/100
Event
Market update
Published
11 Jul 2026 01:09
Source
Sahm
Longevity.Technology Direct company coverage

BioAge advances inflammaging drug into Phase 2

BioAge has initiated its Phase 2 QUELL-CV trial to evaluate its NLRP3 inflammasome inhibitor, BGE-102, for cardiovascular inflammatory burden. This drug was discovered through human longevity datasets, aiming to address chronic inflammation (inflammaging) which is a key hallmark

Tone
Positive 70/100
Event
Market update
Published
07 Jul 2026 16:12
Source
Longevity.Technology
TradingView Direct company coverage

Price to sales forward of BioAge Labs, Inc. – NASDAQ:BIOA

This article provides the "Price to sales forward" metric for BioAge Labs, Inc. (NASDAQ:BIOA). The data is presented within the context of TradingView's financial overview for the company, accessible through its platform.

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 03:41
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of BioAge Labs, Inc. – DUS:Y7G

This article displays information regarding the "Price to earnings forward" metric for BioAge Labs, Inc. (DUS:Y7G) on the Dusseldorf Stock Exchange. It indicates that no specific value, change, or percentage change for this financial metric was available at the time of publicatio

Tone
Neutral 50/100
Event
Earnings
Published
07 Jul 2026 00:39
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of BioAge Labs, Inc. – DUS:Y7G

This page from TradingView provides financial information for BioAge Labs, Inc. (DUS:Y7G), specifically focusing on its Enterprise Value to EBITDA forward. The content indicates that market data is provided by ICE Data Services and FactSet, highlighting key financial metrics for

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 21:40
Source
TradingView
Investing.com Direct company coverage

Bioage Labs stock hits 52-week high at 25.8 USD

Bioage Labs (BIOA) stock recently hit a 52-week high of $25.8, currently trading at $25.53 with a market capitalization of $1.12 billion, reflecting a 486% increase over the past year. This surge is supported by positive developments, including the dosing of the first participant

Tone
Positive 70/100
Event
Market update
Published
06 Jul 2026 14:41
Source
Investing.com
Sahm Direct company coverage

Why BioAge Labs (BIOA) Is Up 6.3% After Starting QUELL-CV Phase 2 Trial For BGE-102

BioAge Labs (BIOA) has started its QUELL-CV Phase 2 trial for BGE-102, an oral NLRP3 inhibitor targeting cardiovascular risk reduction, leading to a 6.3% increase in its stock price. This move advances the company's pipeline and focuses investor attention on its inflammation-targ

Tone
Positive 71/100
Event
Market update
Published
03 Jul 2026 23:40
Source
Sahm
Moomoo Direct company coverage

Bioage Labs Insider Sold Shares Worth $1,576,752, According to a Recent SEC Filing

An insider at Bioage Labs recently sold shares totaling $1,576,752, as detailed in a recent SEC filing. This transaction provides insights into insider activities at the company, which can often be a point of interest for investors.

Tone
Negative 30/100
Event
Market update
Published
01 Jul 2026 21:40
Source
Moomoo
Stock Titan Direct company coverage

[Form 4] BioAge Labs, Inc. Insider Trading Activity

BioAge Labs, Inc.'s Principal Accounting Officer, Shane Barton, engaged in insider trading activity by exercising stock options and selling common stock shares in late June. These transactions, totaling 62,566 shares sold for approximately $1.58 million, were executed under a pre

Tone
Negative 30/100
Event
Market update
Published
01 Jul 2026 20:53
Source
Stock Titan
Investing.com Direct company coverage

BioAge Labs principal accounting officer sells $1.57m in stock

Shane Barton, Principal Accounting Officer at BioAge Labs, Inc. (NASDAQ:BIOA), sold 62,566 shares of the company's common stock for approximately $1.57 million between June 29 and June 30, 2026. These sales occurred after Barton acquired 59,934 shares through stock options and we

Tone
Negative 35/100
Event
Market update
Published
01 Jul 2026 20:40
Source
Investing.com
Investing.com Canada Direct company coverage

BioAge Labs principal accounting officer sells $1.57m in stock By Investing.com

BioAge Labs' principal accounting officer, Shane Barton, sold 62,566 shares of BioAge Labs (NASDAQ: BIOA) common stock for approximately $1.57 million across two trading days. These sales occurred after Barton exercised stock options to acquire 59,934 shares and were executed und

Tone
Negative 39/100
Event
Market update
Published
01 Jul 2026 20:39
Source
Investing.com Canada
Investing.com Canada Direct company coverage

Form 4 Bioage Labs Inc For: 1 July By Investing.com

This article reports on a Form 4 filing by Bioage Labs Inc. for July 1st, published by Investing.com. It also includes a stock market overview with various indices, commodity prices, and individual stock performances, alongside popular news headlines.

Tone
Neutral 50/100
Event
Macro sensitivity
Published
01 Jul 2026 20:39
Source
Investing.com Canada
Stock Titan Direct company coverage

BIOA (NASDAQ: BIOA) Form 144 filed for 42,350-share proposed sale

BioAge Labs, Inc. (NASDAQ: BIOA) has filed a Form 144 indicating a proposed sale of 42,350 shares tied to a stock option exercise, with a planned sale date of June 30, 2026. The filing also reports a recent sale of 42,350 shares on June 29, 2026, generating $1,067,577.87, with Fi

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 20:22
Source
Stock Titan
Investing.com Canada Direct company coverage

Form 144 BioAge Labs For: 29 June By Investing.com

This article from Investing.com announces the filing of Form 144 for BioAge Labs on June 29. It briefly mentions the stock symbol BIOA, which saw a 5.01% increase, and is published by © Reuters. The content mainly consists of market data and unrelated trending news and stock perf

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 21:09
Source
Investing.com Canada
Stock Titan Direct company coverage

BIOA (BIOA) Form 144 lists proposed sales of 2,632 and 39,718 shares

BioAge Labs, Inc. (BIOA) has filed a Form 144 notice with the SEC, indicating proposed sales of Common stock. The filing details two transactions: 2,632 "IPO Shares" dated September 26, 2024, and 39,718 shares from a "Stock Option Exercise" dated June 29, 2026. Fidelity Brokerage

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 20:09
Source
Stock Titan
marketscreener.com Direct company coverage

BioAge Labs, Inc.(NasdaqGS: BIOA) added to Russell Microcap Growth Benchmark Index

BioAge Labs, Inc. (NasdaqGS: BIOA) has been added to multiple Russell benchmark indices, including the Russell Microcap Growth, Russell 2000 Growth, Russell 3000E Growth, and Russell Small Cap Comp Growth. This inclusion is a significant milestone for the clinical-stage biopharma

Tone
Positive 73/100
Event
Market update
Published
29 Jun 2026 13:09
Source
marketscreener.com
marketscreener.com Direct company coverage

BioAge Labs, Inc.(NasdaqGS: BIOA) added to Russell 2000 Growth Benchmark

BioAge Labs, Inc. (NasdaqGS:BIOA) has been added to the Russell 2000 Growth Benchmark, a significant development for the clinical-stage biopharmaceutical company. The company focuses on developing therapeutic product candidates for metabolic diseases, such as obesity, by targetin

Tone
Positive 86/100
Event
Market update
Published
29 Jun 2026 11:41
Source
marketscreener.com
TradingView Direct company coverage

Enterprise value to EBIT forward of BioAge Labs, Inc. – NASDAQ:BIOA

This article provides a financial metric—enterprise value to EBIT forward—for BioAge Labs, Inc. (NASDAQ: BIOA). It serves as a financial data point without further analysis or contextual information. The content primarily focuses on the stock's listing and basic financial overvie

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 14:41
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of BioAge Labs, Inc. – GETTEX:Y7G

This article provides financial information for BioAge Labs, Inc. (GETTEX:Y7G) focusing on its enterprise value to EBIT forward. The content appears to be a stub or a section of a larger financial data page, primarily presenting market details and navigation links rather than a d

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 01:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of BioAge Labs, Inc. – GETTEX:Y7G

This article provides financial information for BioAge Labs, Inc. (GETTEX:Y7G), specifically focusing on its enterprise value to revenue forward. The content is presented as a market data page, offering an overview of the company's financials on TradingView.

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 19:41
Source
TradingView
Sahm Direct company coverage

BioAge Labs (BIOA) Tests BGE-102 in Phase 2 Trial, But What Does It Signal Strategically?

BioAge Labs has initiated a Phase 2 trial (QUELL-CV) for its drug BGE-102, targeting obesity patients with elevated hsCRP and cardiovascular risk factors. This strategic move aims to validate BGE-102 as a cardiometabolic inflammation therapy, transforming BioAge's investment narr

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 19:41
Source
Sahm
TradingView Direct company coverage

BioAge Labs, Inc. Actuals & Estimates (NASDAQ:BIOA)

This article provides an overview of BioAge Labs, Inc. (NASDAQ:BIOA) stock, including its current price, historical performance, analyst forecasts, and financial data. It highlights the company's significant stock price increase over the last year and offers details on its latest

Tone
Positive 76/100
Event
Analyst action
Published
26 Jun 2026 07:10
Source
TradingView
TradingView Direct company coverage

BioAge Labs, Inc. Actuals & Estimates (GETTEX:Y7G)

This article provides financial actuals and estimates for BioAge Labs, Inc. (GETTEX:Y7G), including its current stock price, historical performance, analyst forecasts, and key financial metrics like revenue, net income, and EBITDA. It also addresses frequently asked questions reg

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 02:09
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of BioAge Labs, Inc. – GETTEX:Y7G

This article provides financial information for BioAge Labs, Inc. (GETTEX:Y7G), specifically focusing on its enterprise value to EBITDA forward. It indicates a lack of current trading data ("No trades") and highlights that the information is made by humans.

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 00:42
Source
TradingView